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Background/Introduction
Patients that require aortic valve replacement, having
previously undergone cardiac surgery, have a higher
morbidity and mortality with increased risks of mediast-
inal injury during re-operation.
Aims/Objectives
In the era of TAVI for high risk surgical candidates, we
analysed our experience with redo conventional surgical
aortic valve replacement (SAVR) and compared these
results with those from patients who had undergone
TAVI as a second heart operation.
Method
A retrospective, observational, comparative study was
performed in the national centre offering TAVI. 149
consecutive patients underwent redo operation with
SAVR (n = 59) or TAVI (n = 90) between October 2012
and February 2015. In the SAVR group patients with
concomitant procedures (n = 8) or endocarditis (n = 8)
were excluded from the analysis.
Results
Mean logistic Euroscore was 29.6 for redo-TAVI com-
pared to 18.6 for redo-SAVR (p < 0.05). Type of pre-
vious cardiac surgery performed in each redo group is
summarised in Table 1.
TAVI access was transfemoral (65.5%), transapical
(6.7%), or trans-aortic (27.8%).
Despite a higher incidence of MACE (major adverse
cardiac events) in SAVR patients, results indicated no
significant differences between two groups in terms of
all-cause and cardiovascular related mortality, stroke,
myocardial infarction.
In details, hospital mortality was higher in SAVR
group (5.1%) compared to TAVI group (2.2%), although
it did not reach statistical significance.
There was a higher incidence of CVA in the SAVR
versus TAVI group (6.8% vs. 2.2%; p = 0.385).
Patients were found to require permanent pacemaker
insertion more often after TAVI (10% vs 3.4%; p = 0.2).
Finally, average length of post-operative hospital stay
was significantly shorter in TAVI than SAVR group
(5.4 vs 10.4 days ; p < 0.00001).
Discussion/Conclusion
This retrospective analysis suggests that TAVI is prefer-
able to SAVR in this high risk group of patients. Redo-
SAVR remains a valid option for younger patients in
whom long-term durability of the prosthetic valve is a
concern.
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Table 1
Previous Cardiac Surgery Redo-SAVR Redo-TAVI
CABG 20 82
AVR 28 2
AVR + CABG 1 0
MVR 6 4
Congenital 4 0
Other Cardiac 0 2
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